投资者

/投资者
投资者 2018-05-30T18:41:16+00:00

Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

4.03
0.00 (0.00%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :49,890
Date :04-18-2019

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed to Present at 3rd Annual Clinical Trials Summit

四月 11th, 2019|Oramed to Present at 3rd Annual Clinical Trials Summit已关闭评论

NEW YORK, April 11, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the [...]

Oramed Patent Allowed in the U.S. for Oral Exenatide

四月 4th, 2019|Oramed Patent Allowed in the U.S. for Oral Exenatide已关闭评论

NEW YORK, April 4, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the [...]

Oramed to Present at H.C. Wainwright Global Life Sciences Conference

四月 3rd, 2019|Oramed to Present at H.C. Wainwright Global Life Sciences Conference已关闭评论

NEW YORK, April 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in [...]

Oramed Patent Allowed in the U.S. for Key Aspect of Its Oral Delivery Technology

三月 28th, 2019|Oramed Patent Allowed in the U.S. for Key Aspect of Its Oral Delivery Technology已关闭评论

NEW YORK, March 28, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the [...]